Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 422 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Coronavirus Vaccines and People with Cancer: A Q&A with Dr. Steven... February 10, 2021 EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan October 25, 2021 Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer October 6, 2021 Is there a future without Pap testing? October 21, 2020 Load more HOT NEWS Ivosidenib with Chemotherapy New Option for Some People with AML Daughter Surprises Terminally Ill Mom With Graduation Ceremony In Hospital Room. Cancer Research UK report highlights stark cancer inequalities across Scotland GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations
